Hye Ryun Kim
Severance Hospital · Yonsei University Health System, Severance Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hye Ryun Kim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07640932 · Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung CancerYonsei University · not yet recruiting · Carcinoma, Small Cell Lung · principal investigator
- Ph2NCT06268210 · Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerYonsei University · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT06250777 · Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesYonsei University · enrolling by invitation · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT05786430 · Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior LazertinibYonsei University · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT05286060 · Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck CancerYonsei University · active not recruiting · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT04910347 · Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaYonsei University · active not recruiting · Locally Advanced Nasopharyngeal Carcinoma · principal investigator
- N/ANCT04603248 · A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaYonsei University · completed · Head and Neck Squamous Cell Carcinoma (HNSCC) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 35 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:26 UTC. The ranking covers the 200 most relevant of 130 PubMed records, and a shared surname and initials can bring in a namesake. All 130 on PubMed
- Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.N Engl J Med · 20172,905 citationsRCR 97.2
- 1,050 citationsRCR 71.3
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2018824 citationsRCR 27.7
- 661 citationsRCR 25.8
- CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).J Clin Oncol · 2018439 citationsRCR 15.5
- Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.J Thorac Oncol · 2021359 citationsRCR 18.4
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.Cancer Discov · 2020274 citationsRCR 10.1
- Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.J Clin Oncol · 2020263 citationsRCR 10.0
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.J Clin Oncol · 2021254 citationsRCR 12.1
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.J Clin Oncol · 2017248 citationsRCR 7.3